Book a Meeting

Anti-Transforming growth factor beta Antibody, Non-Fucosylated (BioBet-1339ZP) (CAT#: BioBet-1339ZP) Datasheet

Target
Transforming growth factor beta
Isotype
IgG1
Description
Anti-Transforming growth factor beta Antibody, Non-Fucosylated (BioBet-1339ZP) is a humanized monoclonal IgG1 antibody against Transforming growth factor beta. This product is an ADCC enhanced antibody produced by our Afuco™ platform.
Antibody Indication
Kidney Disease
Classification
Therapeutic antibody; biobetter

Cooperation Seeking

Creative Biolabs is interested in collaborating with potential partners (include but not limit to major pharma or biotech firms) to further co-develop ADCC-enhanced Transforming growth factor beta antibody. For commercial partners interested in our ADCC-enhanced therapeutic antibodies, Creative Biolabs welcomes collaboration. Here are two ways for your choice, and please contact us for more details.
1) Collaborate with us and co-develop the programs from discovery phase to IND enabling. Costs will be shared.
2) Become a licensed candidate of our programs.
Looking forward to cooperating with you in the near future.
Official Name
TGFB1
Full Name
transforming growth factor, beta 1
Background
This gene encodes a member of the transforming growth factor beta (TGFB) family of cytokines, which are multifunctional peptides that regulate proliferation, differentiation, adhesion, migration, and other functions in many cell types. Many cells have TGFB receptors, and the protein positively and negatively regulates many other growth factors. The secreted protein is cleaved into a latency-associated peptide (LAP) and a mature TGFB1 peptide, and is found in either a latent form composed of a TGFB1 homodimer, a LAP homodimer, and a latent TGFB1-binding protein, or in an active form composed of a TGFB1 homodimer. The mature peptide may also form heterodimers with other TGFB family members. This gene is frequently upregulated in tumor cells, and mutations in this gene result in Camurati-Engelmann disease.
Alternative Names
TGFB1; transforming growth factor, beta 1; CED; LAP; DPD1; TGFB; TGFbeta; transforming growth factor beta-1; TGF-beta-1; latency-associated peptide; prepro-transforming growth factor beta-1
Gene ID
7040
Cellular Localization
Extracellular region or secreted
Involvement in Disease
Diseases associated with TGFB1 include Camurati-Engelmann Disease and Inflammatory Bowel Disease, Immunodeficiency, And Encephalopathy.
Related Pathways
Its related pathways are Simplified Interaction Map Between LOXL4 and Oxidative Stress Pathway and Transcriptional activity of SMAD2/SMAD3-SMAD4 heterotrimer.
Function
Transforming growth factor-1 preprotein: Delay associated peptide (LAP) and transforming growth factor-1 (tgf-1) chain precursors, which constitute the regulatory and active subunits of tgf-1, respectively.
Field of research
Cancer antibody; Cell Biology and Cellular Response antibody; Developmental Biology antibody; Metabolism antibody; Signaling Transduction antibody
Post-translational modifications
Glycosylated. The precursor is cleaved into mature TGF-beta-1 and LAP, which remains non-covalently linked to mature TGF-beta-1 rendering it inactive.
Biologic Classification
Protein Based Therapies
Monoclonal antibody (mAb)
Antibody Isotype
IgG1
Antibody Clone
BioBet-1339ZP
Host
Humanized
Species Reactivity
Human
Description
LY 2382770 is a monoclonal antibody inhibitor of transforming growth factor-beta (TGF-β) kinase, for the treatment of kidney disease due to diabetes.
Antibody Indication
Kidney Disease

Kidney Disease

All products and services are for Research Use Only. Do Not use in humans.

ONLINE INQUIRY

Creative Biolabs has established a team of customer support scientists ready to discuss ADCC/CDC optimization strategies, antibody production, bioinformatics analysis and other molecular biology/biotechnology issues.

  • *
  • *
  • *
USA

UK

Germany

ISO 9001 Certified - Creative Biolabs Quality Management System.